News & Updates
Bluestar Genomics Presents New Data Showing its Liquid Biopsy Test Detects Pancreatic Cancer Signal.
-Analytical performance data presented at the American Pancreatic Association meeting- -The company also appointed seasoned industry leader Jim Vaughn as its chief commercial officer- Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Bluestar Genomics, an innovative company leading the development of next-generation liquid biopsy approaches to early cancer detection, today announced the presentation of new analytical…
Read More
Sustained decrease in proteinuria observed in subgroup of patients with systemic lupus erythematosus, without lupus nephritis, following two doses of itolizumab Dose dependent decreases in inflammatory marker CD6 following itolizumab administration Excerpt from the Press Release: LA JOLLA, Calif.–(BUSINESS WIRE)–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory…
Read More
— STAR-0215 Demonstrates High Potency to Inhibit Plasma Kallikrein Preclinically — — Preclinical Data Show STAR-0215’s Extended Plasma Half-Life, Predicting Long Duration of Action — Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today presented new preclinical data that included demonstration of…
Read More
— Positive topline clinical data from MGTA-145 investigator-initiated Phase 2 clinical trial in multiple myeloma — — Successful conditioning with monotherapy CD117 antibody drug conjugate in a primate model of transplant for gene therapy of sickle cell disease — — Successful conditioning with CD117 antibody drug conjugate in combination with lymphodepleting antibodies leading to effective…
Read More
Excerpt from the Press Release: LAUSANNE, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it is extending its research partnership with leading scientists at the Center for Neurodegenerative Disease Research at the Perelman School of Medicine…
Read More
Excerpt from the Press Release: Philadelphia, PA, November 4, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today presented SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021).…
Read More
COVAXIN™ (BBV152) was recently awarded Emergency Use Listing by the World Health Organization Pediatric EUA submission based on immuno-bridging clinical trial in children, ages 2-18, demonstrating comparable neutralizing antibody response as seen in a large adult Phase 3 clinical trial conducted in India COVAXIN™ (BBV152) uses same Vero Cell manufacturing platform as other childhood vaccines,…
Read More
Excerpt from the Press Release: REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, announced today the dosing of the first subject in a Phase 1 study…
Read More
Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, Nov. 4, 2021 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application…
Read More
Excerpt from the Press Release: SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) — Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?